Anavex Life Sciences Corp (AVXL)

[12x]

Anavex is using the 5% annual stock dilution to cover 40M annual burn rate according to the most recent 10Q , an excellent strategy with minimal dilution if SP can keep above $8.

It also revealed the company already received 2nd installment of the MJF funding, so the Parkinson’s P3 trial start is imminent.

As of June 30, 2023, the Company had received $995,862 in a research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX®2-73 related to Parkinson’s disease. Of the total, $497,931 was received during the nine months ended June 30, 2023, and $497,931 was received during the year ended September 30, 2021.

In January 2021, we were awarded a research grant of $1.0 million from The Michael J. Fox Foundation for Parkinson’s Research to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson’s disease.